institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 20 hours ago • loading... • Updated 20 hours ago

Across 8 Trials, Ruxolitinib Cream Shows Favorable Safety in Pediatric AD

Summary by ajmc.com

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

Across 8 Trials, Ruxolitinib Cream Shows Favorable Safety in Pediatric AD

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).

20 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated17 hours agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ajmc.com broke the news in 20 hours ago on Friday, July 25, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read 1 out of your 5 free daily articles.